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Abstract
Coronary artery stenosis is a thickening of intimal coronary artery due to chronic
inflammation of blood vessels, characterized by the accumulation of inflammatory
cells, vascular smooth muscle cells, lipid, and fibrotic tissue. Resistin, a cysteine-rich
secretory protein, produced bymonocytes and adipose cells, increases proinflammatory
cytokines. This study was conducted to analyze the association between serum resistin
level with the severity of coronary artery stenosis. This cross-sectional study was
performed in 60 patients aged 30-70 years old who were suspected to have coronary
heart disease (CHD) and underwent coronary angiography at Cardiology Department
of Dr. Moewardi Hospital in Surakarta. The cutoff point of serum resistin level was
determined by receiver operating curve (ROC). The data were analyzed to determine
the prevalence ratio of each variable, followed by logistic regression, p<0.05 was
considered statistically significant. This study found a significant association between
serum resistin level and the severity of coronary artery stenosis. At the cutoff point of
6.37 ng/ml, bivariate and multivariate analysis showed that resistin had the prevalence
ratio (PR) of 6.56 (95% CI: 1.705-25.263; p = 0.005) and 7.47 (95% CI: 1.562-35.784; p
= 0.012), respectively. Even after adjustment with body mass index, sex, hypertension,
dyslipidemia and type 2 DM, resistin showed significant association with the severity of
coronary artery stenosis (PR: 7.48; 95% CI: 1.562-35.784; p = 0,012).
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1. Introduction
According to the World Health Organization, coronary heart disease (CHD) is the lead-
ing cause of mortality, especially in developing countries [1]. The prevalence of CHD
in Indonesia has been reported to be 0.5% and keeps escalating since the risks of
CHD such as hypertension, dyslipidemia, age, obesity, high saturated fat in the diet and
sedentary lifestyle are rocketing as well [2].
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Coronary artery stenosis is thickening of intimal coronary artery due to chronic inflam-
mation of blood vessel characterized by the accumulation of inflammatory cells, vascular
smooth muscle cells, lipid and connective tissue [3, 4]. Stenosis disturbs myocardial
oxygenation and CHD symptoms emerge. Mild coronary artery stenosis of less than 50%
arterial lumen does not frequently precipitate clinical symptoms of CHD. Moderate and
severe stenosis results clinical symptoms, with stenosis of >50% causes disturbance of
coronary artery vasodilatation, while stenosis of >75% causes clinical symptoms such as
angina pectoris, acute myocardial infarction and cardiac arrest [5, 6]. The gold standard
for diagnosing coronary artery stenosis is coronary angiography, but it is expensive,
invasive and requires advance equipment [7, 8].
The ”response to injury” is the most commonly applied theory of atherosclerosis.
Endothelial dysfunction due to endothelial injury results in proinflammatory cytokines
and adhesion molecules release and vasoconstriction. Proinflammatory cytokines
attract monocytes from the vessel which then differentiate into macrophages. Monocyte
will release various cytokines leading to chronic inflammation of blood vessels [9, 10].
One of proinflammatory cytokines produced by monocyte is resistin, or “resistin-like
molecule” (RELMs) or “Found In Inflammatory Zone” (FIZZ) cytokine, a cysteine-rich
secretory protein with molecular weight of 12.5 kDa, produced also by adipocyte stroma.
Resistin was expressed on the surface of monocyte. It increases monocyte adhesion to
the endothelial cell, lengthen the lifetime ofmonocyte, stimulatemonocyte accumulation
on tunica intima of the vessel, enhances vascular smooth muscle cell proliferation, foam
cell formation and production of reactive oxygen species [11–13]. Previous studies con-
firmed that resistin has proatherogenic activity and play an important role in progressive
coronary stenosis [14]. This study was conducted to analyze the association between
serum resistin level with the severity of coronary artery stenosis.
2. Methods
This cross-sectional study was conducted to analyze the association of serum resistin
level to the significance of coronary stenosis. The study subjects were 60 CHD patients
hospitalized in June 2017 at cardiology ward of Dr Moewardi Hospital at Surakarta,
Central Java, Indonesia. Subjects aged 30-70 years old. We included the patients who
underwent angiography for the first time and agreed to be enrolled in the study by
signing informed consent. Patients with acute and chronic inflammation characterized
by CRP level of >10 mg/dL, history of hyperthyroidism or receiving antithyroid therapy,
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hyperglycemic stress and patients receiving dexamethasone or statin therapy for more
than 12 weeks were excluded from our study.
Subject’s demography and clinical characteristics were retrieved from anamnesis and
medical records. Physical examination was performed to complete the clinical informa-
tion. Simple anthropometric measurements including weight and height to calculate BMI
were performed for evaluation of obesity. The significance of coronary stenosis was
assessed by coronary angiography and categorized into significant (if luminal narrowing
of the coronary artery is ≥ 50%) and not-significant (if luminal narrowing of the coronary
artery is <50%) [15].
The arterial blood of 4 ml in volume was taken via femoral artery during insertion
of the coronary catheter before coronary angiography procedure. The serum was
obtained after centrifugation of 3000 rpm for 15 minutes and divided into 2 tubes.
Analysis of biochemical parameters performed on these blood samples including serum
resistin, C-Reactive Protein, High-Density Lipoprotein-Cholesterol (HDL-C), Low-Density
Lipoprotein-Cholesterol (LDL-C), triglyceride and glucose. This analysis was performed
by using automatic Advia 1800 chemistry analyzer system. After blood collection, the
tubes for measurement of serum resistin were stored immediately at -80∘C until analysis.
Level of serum resistin was measured by enzyme-linked immune-sorbent assay (ELISA)
by using commercial kits: human ResistinELISADEE050 (Demeditec Diagnostic GMBh,
Germany). The study was approved by the local ethics committee and informed consent
was obtained from all subjects.
Data were tested for normal distribution using the Kolmogorov–Smirnov test. Data
were expressed as mean ± SD or median and percentile 25𝑡ℎ—75𝑡ℎ in accordance to
their distribution. Categorical data were presented as frequency and percentage. Vari-
ables normally distributed were compared by unpaired Student’s t-test. Variables not
normally distributed were compared by Mann-Whitney U-test. Serum resistin cutoff was
calculated with the ROC curve. Diagnostic sensitivity and specificity for serum resistin
level were calculated using a 2x2 table. To find out the association between serum
resistin and the significance of coronary stenosis, we used bivariate and multivariate
analysis with logistic regression to control other variables affecting the significance of
stenosis such as sex, body mass index (obesity if BMI >25), history of hypertension,
history of type 2 diabetes mellitus and history of dyslipidemia. The analysis was per-
formed by SPSS statistical software package program version 23, p-value < 0.05 was
considered significant.
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3. Results
Demographic and biochemistry characteristics of the subjects have been summarized
in Table 1. The mean age of subjects was 58.3±9.2 years old, 71.7% were male and the
incidence of significant coronary stenosis was 78.3%. Amongst demographic variables,
history of hypertension were the only significant variables differ between non-significant
and significant coronary stenosis (p=0.041). Serum resistin level also differs significantly
between the two groups (p=0.008).
The cutoff value for serum resistin level was calculated using the ROC curve. Diagnos-
tic sensitivity and specificity for serum resistin level were calculated using a 2x2 table. At
the cut off value of 6.37 ng/mL serum, resistin has an area under the curve (AUC) of 0.707
(95%CI: 0.543-0.870; p=0.028) with sensitivity and specificity for coronary stenosis were
64.6% and 75%, respectively. This resistin cutoff then is used in the further analyses.
Bivariate analysis demonstrated an association between serum resistin level and sig-
nificant coronary stenosis with the prevalence ratio (PR) of 6.56 (95%C I: 1.71-25.26;
p=0.005). Hypertension also associated with the significance stenosis with PR of 3.82
(95%CI: 1.06-13.77; p=0.041) (Table 2).
The result of logistic regression multivariate analysis between serum resistin level
and other variables affecting the significance of coronary stenosis was demonstrated
in Table 3. After adjustment for history of hypertension (model 1), serum resistin level
revealed the association with significant coronary stenosis with the PR 5.69 (95%CI 1.43-
22.67; p=0.014). In all models, even after adjustment for history of hypertension, history
of dyslipidemia, BMI, sex and history of type 2 DM, serum resistin level of ≥ 6.37 ng/ml
still demonstrated an association with significant coronary stenosis. History of hyperten-
sion also showed an association with significant coronary stenosis after adjustment for
history of dyslipidemia, BMI, sex, and history of type 2 DM. History of dyslipidemia, BMI,
sex, and history of type 2 DM had no association with significant coronary stenosis.
4. Discussion
The present study evaluated the association between the serum resistin level with the
significance of coronary stenosis. In significant coronary artery stenosis (luminal narrow-
ing of the coronary artery is ≥ 50%), coronary artery wall losses its ability to vasodilate,
then myocardial oxygenation disturbed. If the coronary stenosis is severe (>75%), clin-
ical symptoms will occur [5, 6]. In this study, significant stenosis occurred in 78.3% of
subjects.
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Table 1: Demographic and biochemistry characteristics of the subjects.
Total Coronary stenosis p
n=60 (100%) Not-significant Significant
[n= 13 (21.7%)] [n=47 (78.3%)]
Sex (%)𝑎
Male 43 (71.7%) 10 (76.9%) 33 (70.2%) 0.461
Female 17 (28.3%) 3 (23.1%) 14 (29.8%)
Age (year)𝑏 58.3 ± 9,2 53.90 ± 9.02 59.56 ± 8.94 0.05
BMI (kg/m2)𝑏 23.61 ± 2.93 23.04 ± 2.61 23.76 ± 3.03 0.44
BMI category (%)
Normal 42 (70%) 9 (69.2%) 33 (70.2%) 0.597
Obesity 18 (30%) 4 (30.8%) 14 (29.8%)
BP systolic (mmHg)𝑏 141.6 ± 28.56 136.92 ± 30.72 142.87 ± 28.14 0.511
BP diastolic (mmHg)𝑏 85.0 ± 15.18 83.08 ± 15.57 85.53 ± 15.51 0.61
History of hypertension (%)𝑎
No 18 (30%) 7 (53.8%) 11 (23.4%) 0.041*
Yes 42 (70%) 6 (46.2%) 36 (76.6%)
History of type 2 DM (%)𝑎
No 39 (65%) 8 (61.5%) 31 (66%) 0.505
Yes 21 (35%) 5 (38.5%) 16 (34%)
History of dyslipidemia (%)𝑎
No 24 (40%) 5 (38.5%) 19 (40.0%) 0.58
Yes 36 (60%) 8 (61.5%) 28 (59.6%)
NFBG (mg/dl)𝑐 128.3
(100.2-133.75)
121.85 (114-132.5) 130.09 (99 – 134) 0.607
LDL-C (mg/dl)𝑏 120.55 ± 36.76 123.08 ± 28.81 119.85 ± 38.92 0.782
HDL-C (mg/dl)𝑏 38.87 ± 9.8 42.38 ± 6.69 37.89 ± 10.35 0.145
Triglyceride (mg/dl)𝑏 141.52 ± 69.98 174.15± 81.05 132.49 ± 64.68 0.057
Serum resistin level (ng/mL)𝑐 7.92 (5.68 – 8.63) 6.02 (5.07 – 7.64) 8.39 (5.94 – 8.9) 0.008*
BP bloodpressure.
NFBG non-fastingbloodglucose.
LDL-C low-density lipoprotein cholesterol.
HDL-C high-density lipoprotein cholesterol.
𝑎categorical data.
𝑏 datanormallydistributed.
𝑐 data not normallydistributed.
*p significant if <0.05.
The median and percentile 25𝑡ℎ—75𝑡ℎ of resistin level differ significantly between
significant and not-significant stenosis group [8.39 (5.94 – 8.9) vs 6.02 (5.07 – 7.64),
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Table 2: Bivariate analysis of serum resistin level and other variables affecting the significance of coronary
stenosis.
Variable Coronary stenosis PR (95%CI) p
Not-significant Significant
Serum resistin level(ng/mL)
< 6.37 9 12 6.56 (1.71-25.26) 0.005*
≥ 6.37 4 35
Sex
Male 10 33 0.77 (0.17-2.97) 0.461
Female 3 14
BMI category
Normal 9 33 0.95 (0.25- 3.62) 0.597
Obesity 4 14
History of hypertension
No 7 11 3.82 (1.06-13.77) 0.041*
Yes 6 36
History of type 2 DM
No 8 31 0.83 (0.23- 2.94) 0.505
Yes 5 16
History of dyslipidemia
No 5 19 0.92 (0.26-3.25) 0.58
Yes 8 28
*p value is significant if <0.05
p=0.008). Bivariate analysis showed that a serum resistin level of ≥ 6.37 ng/mL is sig-
nificantly associated with the degree of coronary stenosis. Pathophysiologically, coro-
nary stenosis caused by atherosclerosis is a sustained chronic inflammation. The more
severe the stenosis, the atherosclerotic lesion is thicker. More monocytes will differ-
entiate into macrophage, then accumulate inside the coronary intima, leading to more
resistin released into circulation [14]. This finding is similar to those reported by Krecki
et al [16] and Ohmori et al [17] but it is contradictory from that of Mortavazi et al’s study
[18].
Bivariate analysis also revealed a significant association between histories of hyper-
tension with the significance of coronary stenosis. Ohmori et al [17] and Kelley et al [19]
suggested that a history of hypertension was significantly associated with the degree of
coronary stenosis, which is similar to our study. Angiotensin II will cause vasoconstric-
tion, aldosterone secretion, vascular smooth muscle cell proliferation, fibrosis, superox-
ide formation, inflammation, and thrombosis, resulting in endothelial dysfunction. Hyper-
tension results in coronary artery wall spasm so that vasodilatation decreases and coro-
nary luminal narrows [10].
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Table 3: Multivariate analysis of serum resistin level andother variables affecting the significance of coronary
stenosis.
Variable PR 95%CI p
Model 1
Serum resistin≥ 6.37 ng/mL 5.69 1.43-22.67 0.014*
History of hypertension 3.04 0.77-12.03 0.114
Model 2
Serum resistin≥ 6.37 ng/mL 6.73 1.58-28.61 0.010*
History of hypertension 4.49 0.94-21.35 0.059
History of dyslipidemia 0.35 0.07-1.75 0.2
Model 3
Serum resistin ≥ 6.37 ng/mL 6.99 1.62-30.18 0.009*
History of hypertension 4.61 0.98-21.85 0.054
History of dyslipidemia 0.36 0.07-1.83 0.221
BMI 0.67 0.14-3.10 0.609
Model 4
Serum resistin ≥ 6.37 ng/mL 7.72 1.63-36.35 0.010*
History of hypertension 4.71 1.01-22.14 0.049*
History of dyslipidemia 0.33 0.06-1.76 0.197
BMI 0.65 0.14-3.03 0.582
Sex 1.44 0.26-7.87 0.676
Model 5
Serum resistin ≥ 6.37 ng/mL 7.48 1.56-35.78 0.012*
History of hypertension 5.01 1.02-24.66 0.047*
History of dyslipidemia 0.31 0.05-1.77 0.186
BMI 0.66 0.14-3.11 0.602
Sex 1.41 0.26-7.76 0.696
Historyoftype 2 DM 0.74 0.16-3.45 0.707
*p significant if <0.05.
Based on our finding, BMI has no significant association with coronary stenosis. This
confirms the study conducted by Rossi et al [20] but differs from de Leon et al’s study [12].
Body mass index cannot be used to measure body fat directly and it does not denote
body fat distribution. Fat distribution is the more significant variable for cardiovascular
risk, insulin resistance, type 2 DM, atherosclerosis and other diseases compared to BMI
and waist circumference is a representation of the body fat distribution [21].
History of diabetes is not associated with significant stenosis. Glycemic control plays
a more important role in the pathophysiology of atherosclerosis and coronary stenosis
than random or fasting blood glucose. The accumulation of advanced glycation end
products (AGEs) affects arterial wall more, which will induce proinflammatory cytokines
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release. Chronic hyperglycemia is a trigger for the occurrence of oxidative stress which
promotes atherosclerosis [22].
In our study, history of dyslipidemia was not associated with significant stenosis. This
might have resulted from statin therapy given to our subjects with dyslipidemia. Patients
undergoing statin therapy were included in this study only when they used statin for less
than 12 weeks. The use of statin will influence HDL-C, LDL-C and triglyceride level. This
possibly results in no significant association between dyslipidemia and the degree of
coronary stenosis.
Inmultivariate analysis, after adjustment with history of hypertension, history of dyslipi-
demia, BMI, sex and history of type 2DM, serum resistin level of≥ 6.37 ng/ml still demon-
strated a significant association with the coronary stenosis. History of hypertension also
showed an association with the significance of coronary stenosis after adjustment on a
history of dyslipidemia, BMI, sex, and history of type 2 DM.
Our study had several limitations, including relatively small sample size, only 60 sub-
jects were enrolled in our study. Moreover, it was a cross-sectional design and did not
prove causation. A further studywith case-control designwas needed to obtain the odds
ratio in order to clarify this relationship. It is also necessary to give a closed control on
variable type 2 DM and dyslipidemia.
5. Conclusion
Serum resistin level is associated with the significance of coronary stenosis, even after
adjustment of other factors affecting the degree of coronary stenosis. Resistin cutoff
point of ≥6.37 ng/ml has a prevalence ratio of 6.56 (95% CI: 1.71-25.26) for more severe
coronary stenosis.
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